Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis.

Socié, Gérard

Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. [electronic resource] - British journal of haematology 04 2019 - 297-310 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1365-2141

10.1111/bjh.15790 doi


Adolescent
Adult
Aged
Antibodies, Monoclonal, Humanized--adverse effects
Atypical Hemolytic Uremic Syndrome--drug therapy
Child
Child, Preschool
Complement Inactivating Agents--adverse effects
Databases, Factual
Fatigue--chemically induced
Female
Fever--chemically induced
Hemoglobins--deficiency
Hemoglobinuria, Paroxysmal--drug therapy
Humans
Infant
Infant, Newborn
Male
Meningococcal Infections--chemically induced
Middle Aged
Opportunistic Infections--chemically induced
Pharmacovigilance
Pregnancy
Pregnancy Complications--drug therapy
Pregnancy Outcome
Young Adult